QUPPF Stock UPDATES Quindell Portfolio Plc. (QUPPF) 2.7500 09/18/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Quindell Portfolio Plc. (QUPPF) 2.7500 $QUPPF

Ground-breaking Telematics Set to Enter Canadian Marketplace
CNW Group - Thu Sep 19, 6:36AM CDT
Insurance Brokers making consumer choice and protection a priority as IBAO and Quindell set to enter partnership as car insurance technology evolves

UK Legal Services Market Report 2013
M2 - Thu Aug 22, 4:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7xnq5/uk_legal_services) has announced the addition of the "UK Legal Services Market Report 2013" report to their offering. Some Improvement In Revenues In 2013 And 2014 But Consolidation Across The Board From Large Law To The High Street The UK Legal Services Market Report 2013 provides a market review of the UK legal services market. Amidst all the changes in the legal market, one thing that stands out about the last 12 months has been the pace of M&A activity and not just involving larger law firms. Some larger firms are using M&A to grow their market share globally. Others in the private client sector are focusing on the UK and particularly in segments such as personal injury and corporate work. Smaller law firms often see M&A as a defensive measure to join forces and deal more effectively with the challenges of the new legal market. M&A activity on the legal high street has been limited until now but this looks set to change. Annual growth of only 1.6% in market value in 2012 suggests that the recovery in the legal market is still struggling to gather pace. In 2013, revenue growth in the UK legal services market overall is likely to show some improvement over 2012 although market growth will still be modest. Stronger growth is expected in 2014. There are almost 12,000 law firms in the UK. Numerically, the sector may be dominated by small firms but, in revenue terms, power is heavily concentrated amongst the top players. The top 200 law firms claimed 53% of private practice revenues generated in the UK in 2012. Lower down the market many medium and smaller law firms are struggling to grow revenues significantly and are working on low margins and financial pressures. Key issues impacting on the market in the next year or so include: the referral fee ban and changes to the no win, no fee regime in the personal injury market; legal aid funding cuts and a potential reduction in the number of providers able to be licensed for criminal legal aid; client demand for more fixed-fee pricing models, or at least more flexible pricing models; further financial pressures on some law firms. Key Topics Covered: Executive Summary 1. Industry Overview 2. Key Trends 3. Selected Bodies and Associations in Legal Services 4. PEST Analysis 5. IRN Primary Research - In-house Counsel 6. Competitive Structure 7. Future Trends Companies Mentioned - Allen & Overy - BGL Group - Clifford Chance - Clyde & Co - Cooperative Legal Services - DLA Piper - DWF - Freshfields Bruckhaus Deringer - Irwin Mitchell - Linklaters - Parabis Law - Pinsent Masons - Quindell Portfolio - RPC - Slater & Gordon Lawyers - Stewarts Law - Wedlake Bell For more information visit http://www.researchandmarkets.com/research/c7...l_services About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles